MERS-CoV
Vaccines Forecast
Since MERS-CoV was first identified in Saudi Arabia in 2012, WHO has recorded 2,627 laboratory-confirmed cases and 946 deaths across 27 countries, a case fatality rate of around 36%. Transmission has stayed largely contained to the Middle East since 2019, but camel-to-human spillover remains active and WHO/CEPI still rank MERS-CoV a priority pathogen with pandemic potential. Oxford and Barinthus Bio's ChAdOx1 MERS is now advancing toward a CEPI-backed Phase II trial. This is a comprehensive, wide geography commercial assessment of the MERS-CoV vaccine opportunity, drawing on VacZine Analytics' long standing, independent authority in respiratory disease vaccine markets.
- Format
- PDF (~154 slides) + Excel model
- Markets modelled
- Public stockpile & private
- Scenarios
- LO / BASE / HI pricing
- Forecast horizon
- To 2035
- Approach
- Value/volume demand model
- Base edition
- January 2020
- Availability
- Syndicated / bespoke
MERS-CoV cases across 27 countries
reported to WHO since 2012
MERS-CoV RNA in recent surveillance
available today
A camel-borne coronavirus WHO and CEPI still rank a pandemic-potential priority
This review sets out the current disease background, epidemiology and R&D competitive landscape for MERS-CoV, more than a decade on from its identification in Saudi Arabia.
Pathogen overview - MERS-CoV
MERS-CoV, a novel coronavirus first identified in Saudi Arabia in 2012, causes Middle East respiratory syndrome, a severe respiratory illness that WHO and CEPI (the Coalition for Epidemic Preparedness Innovations) class as a priority pathogen with pandemic potential. The virus is enzootic in dromedary camels, and human infection typically follows direct or indirect camel contact, though human-to-human transmission has repeatedly driven larger nosocomial clusters. The best known of these remains the 2015 outbreak, in which MERS-CoV spread from a single travel-linked index case to infect 185 people, a stark illustration of the virus's hospital-outbreak potential. Since 2012, WHO has received reports of 2,627 laboratory-confirmed MERS-CoV cases and 946 associated deaths across 27 countries, a case fatality rate of approximately 36%, though this figure may overstate true lethality given likely underdetection of mild and asymptomatic infections. Saudi Arabia accounts for the substantial majority of confirmed cases, at around 84% (2,209 cases).
Unlike several other emerging pathogens on VacZine Analytics' coverage list, MERS-CoV's geographic footprint has narrowed rather than widened. No MERS-CoV infections have been reported outside the Middle East since 2019. Activity within Saudi Arabia has nonetheless continued at a low, persistent level: five cases and four deaths were reported between January and early December 2024; four cases and two deaths followed between September 2024 and February 2025; and eleven cases with a 22.2% mortality rate were reported between March and April 2025. Camel surveillance continues to confirm an active zoonotic reservoir underlying this ongoing activity: one recent study of 558 camel swabs in Saudi Arabia found 39% positive for MERS-CoV RNA, and around one in five human cases still involves reported camel contact.
Against that backdrop, the vaccine field has continued to advance two credentialed candidates. Oxford's Pandemic Sciences Institute, working with Barinthus Biotherapeutics (formerly Vaccitech, which retains commercialisation rights) and CEPI funding, launched a Phase I trial of ChAdOx1 MERS in Liverpool in September 2023, enrolling 84 participants aged 50 to 70; the programme has since progressed under continued CEPI backing toward Phase II, with recent immunogenicity data confirming an antigen-specific human immune response, though long-term durability data remain limited. Separately, a three-dose MVA-MERS-S regimen has produced the field's most encouraging durability readout to date, with published data showing 75% of participants retaining detectable neutralising antibodies at two years by pseudovirus assay (50% by live-virus assay). CEPI has also partnered with IDT Biologika on MERS-CoV vaccine manufacturing, and continues to draw comparative lessons from its parallel Nipah and Lassa fever programmes.
Two credentialed candidates advance a still-open, high-priority pipeline
A decade after CEPI first flagged MERS-CoV as a priority pathogen, the field finally has both a CEPI-backed clinical candidate progressing toward Phase II and published multi-year durability data from a second platform.
-
Oxford Pandemic Sciences Institute / Barinthus BioAdvancing toward Phase IIChAdOx1 MERS Viral vector, ChAdOx1 platform
A Phase I trial (84 participants, aged 50-70) launched September 2023 in Liverpool; CEPI, Barinthus Bio and Oxford are advancing the programme through Phase II, with recent data confirming antigen-specific immunogenicity in humans. -
MVA-MERS-S development consortium2-year durability data publishedMVA-MERS-S Modified vaccinia Ankara, 3-dose regimen
Published follow-up data show 75% of participants retained detectable neutralising antibodies at two years by pseudovirus assay (50% by live-virus assay), the field's longest-duration durability readout to date. -
Barinthus BiotherapeuticsInfectious disease deprioritisedChAdOx1 MERS sponsor corporate update
Barinthus's 2026 SEC filings (Q1, 30 April 2026; Q2, 6 August 2026) confirm VTP-500 (ChAdOx1 MERS) remains grouped among its deprioritised "Barinthus Legacy Assets" following a January 2025 strategic refocus onto immunology and inflammation; the company expects to complete its previously announced merger with Clywedog Therapeutics in mid/H2 2026, renaming the combined business Clywedog Therapeutics Holdings (Nasdaq: CLYD) and refocusing on metabolic and autoimmune disease. The merger became effective on 3 September 2026, forming Clywedog Therapeutics Holdings; the same Q2 2026 Form 10-Q (filed August 2026) discloses that the company intends to exit the CEPI Funding Agreement backing VTP-500 after CEPI required a $1.0m repayment in Q1 2026 (repaid in Q2 2026), with first-half 2026 R&D spend on the Barinthus Legacy Assets falling to $2.0m from $5.4m in H1 2025. -
CEPI / IDT BiologikaManufacturing partnershipMERS-CoV vaccine manufacturing collaboration
A CEPI-backed manufacturing partnership supporting scale-up of candidate MERS-CoV vaccines, alongside CEPI's parallel Nipah and Lassa fever programmes. -
WHO / Saudi Ministry of HealthActive surveillanceHuman case & camel reservoir monitoring
Continued human case reporting and camel surveillance, including a 39% RNA-positive rate in a recent 558-swab Saudi study, track the ongoing zoonotic reservoir underlying sporadic human clusters.
Oxford and Barinthus Bio's advance of ChAdOx1 MERS toward a CEPI-backed Phase II trial, alongside published two-year durability data for the MVA-MERS-S platform, marks the most credentialed the MERS-CoV vaccine pipeline has been since WHO and CEPI first flagged the virus as a priority pathogen. That progress arrives even as case activity persists at a low, steady level in Saudi Arabia and the camel reservoir remains active, reframing the commercial case across public stockpile and private market segments alike. The VacZine Analytics model quantifies this opportunity under LO/BASE/HI pricing scenarios reflecting differing degrees of pipeline success.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, current R&D status and scenario-based demand forecasting across public stockpile and private markets to 2035.
Value ($m) and volume (million doses) forecasts to 2035 across public stockpile procurement and private preventive/occupational markets.
Full review of Oxford/Barinthus Bio's ChAdOx1 MERS, the MVA-MERS-S platform and the wider MERS-CoV R&D landscape.
Target product profile, launch timeframe assumptions, pricing and market penetration estimates for stockpile and private segments.
Three pricing-justified revenue scenarios reflecting differing pipeline-progression and procurement assumptions.
Global case, death and camel-reservoir surveillance data updated through WHO and CEPI's most recent 2025/2026 reporting.
Comparative analysis of other CEPI-backed procurement and deployment scenarios, including Nipah and Lassa fever, to guide MERS-CoV market assumptions.
A glimpse of the commercial model
The table below shows a partial view of the market-segment and scenario framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Market segment | Geography | Sector | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| Preventative - HCWs & Hajj/Umrah travelers | Saudi Arabia & GCC | Public/private | Pre-licensure | Modelled |
| Stockpile / outbreak response | MENA region & ROW | Public | Pre-licensure | Modelled |
| Occupational - camel workers & abattoir staff | Saudi Arabia & GCC | Private/public | Pre-licensure | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All geographies | All sectors | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the MERS-CoV vaccine opportunity across public stockpile and private markets.
- Executive presentation (~154 slides, PDF) - disease background, epidemiology, R&D status and full commercial assessment with supporting narrative and references
- MS-Excel forecast model - value ($m) and volume (million doses) predictions to 2035 across public stockpile and private market segments
- LO/BASE/HI pricing scenarios - three forecast scenarios based on differing pricing justifications and pipeline outcomes
- Competitor intelligence - Oxford/Barinthus Bio's ChAdOx1 MERS, the MVA-MERS-S platform and the wider MERS-CoV R&D landscape
- Updated epidemiology module - WHO/CEPI 2025-2026 surveillance update covering cumulative and recent case, death and camel-reservoir data
- Comparative CEPI case studies - procurement and deployment case studies from other CEPI initiatives, including Nipah and Lassa fever, with assumptions clearly outlined
Built for organisations weighing the MERS-CoV vaccine opportunity
Most valuable to teams evaluating the MERS-CoV vaccine market against their own pipeline, BD ambitions or investment thesis, now that a CEPI-backed candidate is approaching later-stage trials.
Vaccine developers
Positioning and commercial feasibility assessment for MERS-CoV candidates at any stage, informed by ChAdOx1 MERS's advance toward Phase II.
Corporate strategy & BD
Validate the size and structure of a still-open market with no incumbent vaccine, now that CEPI-backed programmes are approaching later-stage trials.
Investors & analysts
Independent assessment of pipeline risk and commercial upside for due diligence on Barinthus Bio, CEPI-backed programmes and future MERS-CoV entrants.
Public health & pandemic-preparedness bodies
Demand modelling and stockpile planning support, informed by comparative CEPI case studies from Nipah and Lassa fever.
Researchers & academia
Comprehensive epidemiology and R&D landscape for grant, translational and camel-reservoir research planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions across public stockpile and private occupational/travel channels.
VacZine Analytics has tracked respiratory disease vaccine markets since our earliest editions, positioning us to reassess the MERS-CoV vaccine opportunity the moment the field's leading candidates began advancing toward later-stage trials. This is a genuinely comprehensive analysis with a wide geographic focus spanning public stockpile and private market segments, and it has been well received by clients across the field for the depth of its epidemiology and comparative CEPI case-study modelling. Few groups have followed this market as closely, and that recognised, independent expertise underpins everything in the analysis.
This January 2020 edition has been further refreshed to incorporate WHO and CEPI's most recent 2025-2026 surveillance update, confirming 2,627 cumulative cases and 946 deaths across 27 countries, alongside the R&D field's advance to a CEPI-backed Phase II trial for ChAdOx1 MERS and published two-year durability data for MVA-MERS-S. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc MERS-CoV analysis, a briefing call is included on request.